These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33795353)

  • 1. Prediction of treatment dosage and duration from free-text prescriptions: an application to ADHD medications in the Swedish prescribed drug register.
    Zhang L; Lagerberg T; Chen Q; Ghirardi L; D'Onofrio BM; Larsson H; Viktorin A; Chang Z
    Evid Based Ment Health; 2021 Nov; 24(4):146-152. PubMed ID: 33795353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medications for attention-deficit/hyperactivity disorder in individuals with or without coexisting autism spectrum disorder: analysis of data from the Swedish prescribed drug register.
    Johansson V; Sandin S; Chang Z; Taylor MJ; Lichtenstein P; D'Onofrio BM; Larsson H; Hellner C; Halldner L
    J Neurodev Disord; 2020 Dec; 12(1):44. PubMed ID: 33357227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Supervised off-label prescribing of methylphenidate in adult ADHD].
    Carton L; Dondaine T; Deheul S; Marquié C; Brigadeau F; Amad A; Devos D; Danel T; Bordet R; Cottencin O; Gautier S; Ménard O
    Encephale; 2019 Feb; 45(1):74-81. PubMed ID: 30122296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective.
    Pottegård A; Bjerregaard BK; Glintborg D; Kortegaard LS; Hallas J; Moreno SI
    Eur J Clin Pharmacol; 2013 Mar; 69(3):589-98. PubMed ID: 22811260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of sleep disorder diagnoses and sleep medication prescriptions in individuals with ADHD across the lifespan: a Swedish nationwide register-based study.
    Ahlberg R; Garcia-Argibay M; Taylor M; Lichtenstein P; D'Onofrio BM; Butwicka A; Hill C; Cortese S; Larsson H; Du Rietz E
    BMJ Ment Health; 2023 Aug; 26(1):. PubMed ID: 37657817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescriptions for ADHD medication, 2004-08.
    Lillemoen PK; Kjosavik SR; Hunskår S; Ruths S
    Tidsskr Nor Laegeforen; 2012 Sep; 132(16):1856-60. PubMed ID: 22986969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.
    Shyu YC; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Wang LJ
    Clin Ther; 2016 Mar; 38(3):595-602. PubMed ID: 26874787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe.
    Siffel C; Page M; Maxwell T; Thun B; Kolb N; Rosenlund M; von Bredow D; Keja J
    J Child Adolesc Psychopharmacol; 2020 Sep; 30(7):439-447. PubMed ID: 32315539
    [No Abstract]   [Full Text] [Related]  

  • 9. Estimated prevalence and incidence of diagnosed ADHD and health care utilization in adults in Sweden - a longitudinal population-based register study.
    Polyzoi M; Ahnemark E; Medin E; Ginsberg Y
    Neuropsychiatr Dis Treat; 2018; 14():1149-1161. PubMed ID: 29765219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of melatonin in Swedish children and adolescents--a register-based study according to age, gender, and medication of ADHD.
    Furster C; Hallerbäck MU
    Eur J Clin Pharmacol; 2015 Jul; 71(7):877-81. PubMed ID: 25995170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication treatment for attention-deficit/hyperactivity disorder and the risk of acute seizures in individuals with epilepsy.
    Brikell I; Chen Q; Kuja-Halkola R; D'Onofrio BM; Wiggs KK; Lichtenstein P; Almqvist C; Quinn PD; Chang Z; Larsson H
    Epilepsia; 2019 Feb; 60(2):284-293. PubMed ID: 30682219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment adherence and persistence in adult ADHD: results from a twenty-four week controlled clinical trial with extended release methylphenidate.
    Sobanski E; Retz W; Fischer R; Ose C; Alm B; Hennig O; Rösler M
    Eur Psychiatry; 2014 Jun; 29(5):324-30. PubMed ID: 24176644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
    Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
    Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Text Message Intervention to Improve Adherence to Stimulants in Adults With Attention Deficit/Hyperactivity Disorder.
    Biederman J; Fried R; DiSalvo M; Woodworth KY; Biederman I; Noyes E; Faraone SV; Perlis RH
    J Clin Psychopharmacol; 2019; 39(4):351-356. PubMed ID: 31162154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication utilization among adult patients with attention-deficit/hyperactivity disorder after reimbursement criteria change.
    Kim E; Park S; Kim Y; Je NK
    Int Clin Psychopharmacol; 2020 Nov; 35(6):329-337. PubMed ID: 32897929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.
    Pelham WE; Gnagy EM; Burrows-Maclean L; Williams A; Fabiano GA; Morrisey SM; Chronis AM; Forehand GL; Nguyen CA; Hoffman MT; Lock TM; Fielbelkorn K; Coles EK; Panahon CJ; Steiner RL; Meichenbaum DL; Onyango AN; Morse GD
    Pediatrics; 2001 Jun; 107(6):E105. PubMed ID: 11389303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: connecting the dots.
    Poulin C
    Addiction; 2007 May; 102(5):740-51. PubMed ID: 17506151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADHD Medication Trends in Turkey: 2009-2013.
    Öner Ö; Yilmaz EŞ; Karadağ H; Vural M; Vural EH; Akbulat A; Gürsöz H; Türkçapar H; Kerman S
    J Atten Disord; 2017 Dec; 21(14):1192-1197. PubMed ID: 24554298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beliefs regarding medication and side effects influence treatment adherence in adolescents with attention deficit hyperactivity disorder.
    Emilsson M; Gustafsson PA; Öhnström G; Marteinsdottir I
    Eur Child Adolesc Psychiatry; 2017 May; 26(5):559-571. PubMed ID: 27848023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.